基本信息
浏览量:1
职业迁徙
个人简介
I lead a spectrum of clinical studies spanning the spectrum of the disease and ranging from phase I to randomised phase III. The majority of these studies are translational phase II studies investigating novel targeted and immune therapies. Our current interests include cancer immune therapy combinations across all stages and subtypes of breast cancer, novel targeted agents and antibody-drug conjugates - alone or in combination - to overcome resistance, and innovative biomarker-driven trial concepts (including a preoperative window of opportunity platform to evaluate novel immunotherapy combinations in breast cancer).
研究兴趣
论文共 56 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CLINICAL CANCER RESEARCHno. 4 (2024): 767-778
BMC Cancerno. 1 (2023): 792-792
David W. Cescon,Peter Schmid, Hope S. Rugo,Seock-Ah Im,Mastura Md Yusof,Carlos Gallardo,Oleg Lipatov,Carlos H. Barrios,Jose Perez-Garcia,Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero,
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTEno. 5 (2023): 717-727
Ángela Quintana,Enrique Javier Arenas,Cristina Bernadó, José Fernández Navarro, Jonatan González,Anna Esteve-Codina,Teresa Moliné,Merce Marti,Giuseppe Curigliano,Peter Schmid,Vicente Peg,Joaquín Arribas,
Frontiers in immunology (2023): 1149747-1149747
Alejandro Martinez Chibly,Alice Shia,Radia Johnson, Michael S. Hwang,Marc Hafner,Ciara Metcalfe,Kalpit Shah, Michal Slyper, Chris Bolen,Sarah E. Pinder,Alastair M. Thompson,Steven Gendreau,
Cancer Researchno. 5_Supplement (2023): PD10-06
引用0浏览0引用
0
0
Breast Cancer Researchno. 1 (2023): 67-10
Lancet (London, England)no. 10411 (2023): 1423-1433
EUROPEAN JOURNAL OF CANCER (2023): 113393-113393
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn